| Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and Abcb1/Abcg2-deficient mice M Kim, JK Laramy, AS Mohammad, S Talele, J Fisher, JN Sarkaria, ... Drug Metabolism and Disposition 47 (4), 393-404, 2019 | 47 | 2019 |
| Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma BM Marin, KA Porath, S Jain, M Kim, JE Conage-Pough, JH Oh, CL Miller, ... Neuro-oncology 23 (12), 2042-2053, 2021 | 42 | 2021 |
| The influence of the blood–brain barrier in the treatment of brain tumours S Rathi, JI Griffith, W Zhang, W Zhang, JH Oh, S Talele, JN Sarkaria, ... Journal of Internal Medicine 292 (1), 3-30, 2022 | 31 | 2022 |
| Brain distribution of berzosertib: an ataxia telangiectasia and Rad3-related protein inhibitor for the treatment of glioblastoma S Talele, W Zhang, DM Burgenske, M Kim, AS Mohammad, S Dragojevic, ... Journal of Pharmacology and Experimental Therapeutics 379 (3), 343-357, 2021 | 15 | 2021 |
| Central nervous system delivery of the catalytic subunit of DNA-dependent protein kinase inhibitor peposertib as radiosensitizer for brain metastases S Talele, W Zhang, JH Oh, DM Burgenske, AC Mladek, S Dragojevic, ... Journal of Pharmacology and Experimental Therapeutics 381 (3), 217-228, 2022 | 13* | 2022 |
| Influence of transporters in treating cancers in the CNS G Gampa, S Talele, M Kim, A Mohammad, G Jessica, WF Elmquist Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition …, 2019 | 13* | 2019 |
| Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma RS Kenchappa, A Dovas, MG Argenziano, CT Meyer, LE Stopfer, ... Cell reports 39 (12), 2022 | 12 | 2022 |
| Preclinical risk evaluation of normal tissue injury with novel radiosensitizers S Dragojevic, J Ji, PK Singh, MA Connors, RW Mutter, SC Lester, ... International Journal of Radiation Oncology* Biology* Physics 111 (5), e54-e62, 2021 | 11 | 2021 |
| Factors influencing luciferase-based bioluminescent imaging in preclinical models of brain tumor M Kim, SK Gupta, W Zhang, S Talele, AS Mohammad, J Laramy, ... Drug Metabolism and Disposition 50 (3), 277-286, 2022 | 9 | 2022 |
| Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting … DM Burgenske, S Talele, JL Pokorny, AC Mladek, KK Bakken, BL Carlson, ... Neuro-oncology 24 (3), 384-395, 2022 | 7* | 2022 |
| Central nervous system distribution of the ataxia-telangiectasia mutated kinase inhibitor AZD1390: implications for the treatment of brain tumors S Talele, W Zhang, J Chen, SK Gupta, DM Burgenske, JN Sarkaria, ... Journal of Pharmacology and Experimental Therapeutics 383 (1), 91-102, 2022 | 5 | 2022 |
| CNS delivery of VX-970: A selective ATR inhibitor for radiosensitization in GBM S Talele, A Mohammad, M Kim, D Burgenske, ACM Tuma, JN Sarkaria, ... Cancer Research 79 (13_Supplement), 4858-4858, 2019 | 4 | 2019 |
| Changes in the vasculature of human brain tumors: Implications for treatment W Zhang, S Talele, JN Sarkaria, WF Elmquist Neuro-oncology 23 (12), 1995-1997, 2021 | 2 | 2021 |
| Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma W Zhang, RA Vaubel, JH Oh, AC Mladek, S Talele, W Zhang, KL Waller, ... Molecular cancer therapeutics 23 (1), 47-55, 2024 | 1 | 2024 |
| Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities S Talele, AS Mohammad, JA Schulz, B Bauer, AMS Hartz, JN Sarkaria, ... Drug Delivery to the Brain, 723-762, 2022 | 1 | 2022 |
| A promising blood-brain-barrier penetrant MDM2-p53 antagonist, BI-MDM2, increases survival in orthotopic, glioblastoma patient-derived xenograft models ACM Tuma, S Gupta, S Talele, AS Mohammad, KK Bakken, H He, Z Hu, ... Cancer Research 80 (16_Supplement), 4190-4190, 2020 | 1 | 2020 |
| Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype. RA Vaubel, W Zhang, AC Mladek, TI Pasa, KL Waller, SA Stopka, ... Journal of Clinical Oncology 42 (16_suppl), 2012-2012, 2024 | | 2024 |
| PK-PD-efficacy modeling of brigimadlin in MDM2-amplified glioblastoma. RA Vaubel, W Zhang, DM Burgenske, KL Waller, PA Decker, ML Kosel, ... Journal of Clinical Oncology 42 (16_suppl), 2071-2071, 2024 | | 2024 |
| Differential distribution of the DNA-PKcs inhibitor peposertib selectively radiosensitizes patient-derived melanoma brain metastasis xenografts J Ji, S Dragojevic, CM Callaghan, EJ Smith, S Talele, W Zhang, ... Molecular cancer therapeutics 23 (5), 662-671, 2024 | | 2024 |
| How much is enough? BI-907828: a MDM2-P53 antagonist with limited BBB penetration but potent efficacy in glioblastoma W Zhang, R Vaubel, JH Oh, A Mlade, S Talele, W Zhang, K Waller, ... Drug Metabolism and Pharmacokinetics 55, 100849, 2024 | | 2024 |
